TORONTO, ONTARIO–(Marketwired – May 19, 2016) – Abba Medix Group Inc. (“Abba” or the “Company”) (CSE:ABA) is pleased to announce the appointment of Brad Rogers and David Shpilt to the Board of Directors.
Mr. Rogers brings tremendous experience in the Canadian medical cannabis industry to the Board, having co-founded Mettrum, one of the largest MMPR licenced companies in the country. From its inception, Mr. Rogers acted as the Chief Operating Officer, bringing the company from its MMPR application stage, through to a go public transaction on the TSX Venture Exchange. Mr. Rogers was also an integral part of the multiple financings completed by the company.
“I am looking forward to joining Gerry and the rest of the Board in building the foundation of a strong company,” said Mr. Rogers. “Tremendous opportunity exists in this space and I am looking forward to helping develop a new and innovative business model that will maximize shareholder value for the company in the near term.”
Prior to co-founding Mettrum, Mr. Rogers served as Vice President of Product Realization for one of the world’s largest in-store media marketing companies.
Mr. Shpilt is a highly sought after expert in the medical cannabis industry in Canada, having founded MMG, Medical Marijuana Group (www.medicalmarijuanagroup.ca), an expert legal and medical consulting services firm. MMG provides rehab professionals, litigators and Third Party Insurance Companies a suite of products and services for Cannabinoid Therapy solution for their respective patient populations.
Mr. Shpilt also serves as CEO and Director of Patient Services for one of the industry’s most successful Cannabis Therapy Educational Platforms and provider of Patient Services, Plants Not Pills (www.plantsnotpills.ca).
Mr. Shpilt is also a retired Board Certified Pedorthist and a Manual Osteopathic Practitioner where he first began to work in a clinical setting. Servicing tens of thousands of patients David leveraged into building his first clinic in London, Ontario. Subsequently David has owned and operated companies supplying durable medical equipment, orthopedic appliances and devices to both the Public and Private sectors under contracts and on the open market. He successfully started 12 clinics across Ontario over 9 years, all of which remain highly viable to this date.
“I am delighted to have the opportunity to join the Abba Medix board,” said Mr. Shpilt. “The team that has been assembled bodes well for the future of the company and I look forward to being a part of what I believe to be an excellent opportunity.”
“We are very happy to have Brad and David join our team on the Board at Abba Medix,” said Gerry Goldberg, Interim CEO of Abba Medix. “Brad and David’s wealth of experience and past successes will help Abba achieve its near and long term goals.”
The addition of Mr. Rogers and Mr. Shpilt to the Board further enhances the new business foundation the Company has created. The Company will continue to build out the management and director team over the near term while it works towards completing its strategy of targeted acquisitions.
As part of the restructuring of the Board, Paul Anderson has resigned his position on the Board effective immediately. The company wishes to thank Paul for his tremendous support during its emerging stage.
Abba Medix will continue to provide regular updates regarding progress on its acquisition strategy and operations.
For more information about Abba Medix group, please visit http://www.abbamedix.com.
About Abba Medix Corp.
Abba Medix Group Inc. (CSE:ABA) is the parent company of Abba Medix Corp; a purveyor of fine medical marijuana in Canada. In compliance with Health Canada’s regulations, the company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated medical marijuana marketplace. Abba’s mission is to find, acquire or create joint venture opportunities in patient focused medical marijuana related companies, products, organizational events, sponsorships, educational training, and research and development within medical marijuana sector. For more information please visit www.abbamedix.com.
Cautionary Statements Regarding Forward-Looking Information
Certain statements within this press release relating to the Company constitute “forward-looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and / or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward-looking statements”. Such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to commercial operations, including production and / or sales of medical marijuana, quantities of future medical marijuana production, anticipated revenues in connection with such sales, the overall projected size of the market, completion and / or expansion of production facilities, prospects for future acquisitions, the ability to obtain financing for any future acquisitions, the ability to successfully complete any future acquisitions, and other information that is based on forecasts of future results, estimates of production not yet determinable, and other key management assumptions. Actual results may differ materially from those expressed or implied by such forward-looking statements and involve risk and uncertainties relating to the Company’s historical experience with medical marijuana operations, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, and other uninsured risks. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Further, there can be no assurance that Abba Medix’s medical marijuana license application will be approved by Health Canada, or that any prospective projects in the industry will be successfully completed. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.